|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||2.9600 - 3.1100|
|52 Week Range||2.6300 - 4.4300|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Back in late August, the team at InvestorPlace and I launched a brand-new multimedia initiative called Quick Picks. The goal? Deliver to viewers, for free in a YouTube video that runs less than five minutes, some of my top stocks to buy — quick, actionable insights that could help you score big returns in the market. So far, we’ve executed strongly on half of that goal. The half we are doing really well on? Giving you top stocks to buy. You know, the “picks” part. So far, we’ve delivered 80 picks. About 86% of them have been accurate, with an average return per pick of 60% and a max return of nearly 450%.InvestorPlace - Stock Market News, Stock Advice & Trading Tips The half we are failing at? The “quick” part. We promised 5 minutes or less per video. But I’m an enthusiastic guy. And in these videos, I’m talking about things that I really believe in and get really pumped up about. So, I tend to get carried away some times. The result? Most videos aren’t under 5 minutes. I’ll get better at that part, I promise. But, zooming out, the big picture here is that Quick Picks is providing you a free conduit to tap into 60% average returns per stock pick. That’s a big deal. What’s the secret sauce? It’s simple. We invest in innovation. Here’s a deeper look. Scoring 60% Return With Top Stocks to Buy First, let’s do a quick rundown of the Quick Picks numbers. We started this project back in late August. Our first video was on Chinese tech giant Alibaba (NYSE:BABA). Since then, we’ve delivered 80 unique stock picks. Just over 86% of them have been right (i.e. they have positive returns since we highlighted them in Quick Picks). The average return across all picks? An impressive 60%. For comparison purposes, the S&P 500 is up just 5% over that same stretch. In effect, then, our picks have outperformed the market by 12X. The biggest winner? MindMed (OTCMKTS:MMEDF), which has soared nearly 450% since our October 2 video on the small shroom stock. Jumia (NASDAQ:JMIA) has also soared over 400% since our September 28 video on the African e-commerce platform, as has QuantumScape (NASDAQ:QS) since our September 23 video on the solid-state EV battery pioneer. Another nine picks have scored 100%-plus returns, including NIO (NYSE:NIO), Luminar (NASDAQ:LAZR), Plug Power (NASDAQ:PLUG), The Very Good Food Company (OTCMKTS:VRYYF), and GrowGeneration (NASDAQ:GRWG). Lots of stocks. Across lots of industries. But they all have one thing in common: Innovation. Always Invest in Innovation Our motto at Quick Picks is simple. We always invest in innovation, because the future is an unstoppable force that waits for no one. To highlight this, I often tell readers and viewers to think about the rise of e-commerce, or the shift toward digital advertising, or the spread of mobile phones. Over the past two decades, these innovative and disruptive megatrends have faced a number of “Black Swan” events. We had the dot-com bubble in 2000. The 9/11 attacks in 2001. The Iraq War in the early 2000s. The Great Financial Crisis in 2008/09. European debt crises in the early 2010s. A U.S.-China trade war in back-half of the 2010s. And, of course, a global pandemic in 2020. Yet, through it all, global e-commerce sales rose by 1,269% from 2000 to 2020. North America digital ad sales rose by 1,954%. Mobile phone sales rose by 406%. Get the point? Innovation ignores noise. It powers on, regardless of anything else going on in the world, because the future is an unstoppable force that waits for no one. So, as opposed to fighting this unstoppable force, we align ourselves with it. We invest in it. We invest in innovation. We invest in electric vehicles and self-driving cars. We invest in automation and robotics. We invest in AI and Big Data. We invest in cannabis and psychedelics. We invest in plant food, clean energy, and space. We choose to be a part of the future, and not to hang onto the past. The proof of this strategy is in the pudding — 60% average returns per pick since August. We are highly confident that by continuing to invest in innovation and ignoring the noise, we will sustain this strong performance for the foreseeable future. On the date of publication, Luke Lango did not have (either directly or indirectly) any positions in the securities mentioned in this article. The New Daily 10X Stock Report: Dozens of triple-digit winners, peak gains as high as 926%… 1,326%… and 1,392%. InvestorPlace’s bold new initiative delivers one breakthrough stock recommendation every trading day, targeting gains of 5X… 10X… even 15X and beyond. Now, for a limited time, you can get in for just $19. Click here to find out how. In addition, you can sign up for Luke’s free Hypergrowth Investing newsletter. Click here to sign up now. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post How You Can Score 60% Average Returns per Stock Pick appeared first on InvestorPlace.
Psychedelic stocks could have another “far out” year ahead. For one, the U.S. FDA supports its use, calling drugs, like psilocybin a “breakthrough therapy” in the treatment of severe depression. In fact, according to New York University, psilocybin helped produce substantial, and sustained improvements in anxiety and depression. Two, cities such as Oakland and Santa Cruz, California, and states such as Oregon have just begun to decriminalize its use.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Three, Canada has allowed for the use of psilocybin to assist with end-of-life suffering with cancer, for example. 10 of 2020’s Most Fascinating SPAC Stocks Four, it may only be a matter of time before big pharmaceutical companies begin to take interest in incorporating psychedelics. “As patents on many conventional antidepressants begin to expire – and public and regulatory opinion regarding psychedelics is changing – 2021 will be the time that psychedelic therapy casts a spotlight on the limitations of current mental-health care treatments, and highlights a bold alternative,” as reported by Wired U.K. contributor Robin Carhart-Harris. “The Times They Are A-Changin’” for psychedelics. With that in mind, here are five of the top psychedelic stocks to consider. Mind Medicine (OTC:MMEDF) Cybin Inc. (OTC:CLXPF) Field Trip Health (OTC:FTRPF) Compass Pathways (NASDAQ:CMPS) Mydecine Innovations Group (OTC:MYCOF) Psychedelic Stocks to Buy: Mind Medicine (MMEDF) Source: Shutterstock Over the last few months, the MMEDF stock ran from a low of 33 cents to a high of $5.07. Currently consolidating at $3 a share, I’d like to see the stock test its previous high. As the psychedelics story goes mainstream, the company hopes to use psilocybin, LSD, and ecstasy to help treat mental health issues such as anxiety, addition, and ADHD. In addition, the company just completed its pre-IND (investigational new drug) meeting with the US FDA for LSD-assistance therapy for anxiety disorder. According to the company, “preliminary data has been analyzed for MindMed’s addiction treatment program evaluating the ibogaine derivative 18-MC, which the company has named Project Layla. The preliminary data from the Phase 1 Multiple Ascending Dose (MAD) and Single Ascending Dose (SAD) study has shown that the drug is safe and well tolerated at the doses tested to date, and no Serious Adverse Events (SAEs) have been reported.” Cybin Inc. (CYBN) Source: Shutterstock Since going public in November. CYBN stock ran from a low of 50 cents to a high now of $2. And it could see further upside. The company is working with the Canadian Center for Psychedelic Science to study the safety and efficacy of micro-dosing with psilocybin. The company also just closed on its acquisition of Adelia Therapeutics. The deal will give Cybin a proprietary drug delivery platform to administer psychedelic therapies and bypass liver metabolism. 10 of 2020’s Most Fascinating SPAC Stocks In addition, Cybin wants to bring a psilocybin product targeting major depressive disorder (MDD) with Phase 2 trials scheduled to begin in early 2021. Field Trip Health (FTRPF) Source: luckakcul / Shutterstock.com Another top psychedelic stocks to consider is Field Trip Health. Sine bottoming out at $1.87 in Oct., the stock exploded to a high of $5.50. Now at nearly $3, FTRPF is still worth paying attention to. Field Trip is also attempting to treat people with psilocybin and is working on its lead drug candidate FT-104, a synthetic psychedelic molecule. If preliminary studies for FT-104 are confirmed, it could address the limitation of psilocybin and MDMA. Better, it could make it a top choice for clinicians and provide a better option than psilocybin, as noted by Dieter Weinand, Field Trip board member and former chairman and CEO of Bayer Pharmaceuticals AG. Compass Pathways (CMPS) Source: Shutterstock Compass has become one of the most valuable psychedelic stocks with a market cap of $1.57 billion for several reasons. One, its psilocybin-based treatment, COMP360 is in Phase 2 trials for treatment resistant depression. Two, it just joined the Psychiatry Consortium to help identify and validate treatments to address the unmet needs of people living with mental health issues. Three, the company entered into an agreement with the University of the Sciences in Philadelphia to explore and develop psychedelic and other compounds targeting the 5HT2A receptor, a receptor in the brain that could help with mental health issues. In addition, Compass was also granted a U.K. patent, adding to its U.S. patent and German utility model. Mydecine Innovations Group (MYCOF) Source: Shutterstock MYCOF stock is another one flying high. Since bottoming out at 15 cents, it’s now up to 35 cents and could push higher. At the moment, the company is set to import the first legal shipment of psilocybin mushrooms into Canada thanks to its Health Canada dealer’s license. Once the shipment is in, the psilocybin will be extracted and turned into product for controlled therapeutic purposes. The best part: There’s big opportunity for the company because U.S. expenditures on addiction, depression and PTSD total a staggering $300 billion are doing a terrible job in treating these issues. On the date of publication, Ian Cooper did not have (either directly or indirectly) any positions in the securities mentioned in this article. A contributor to InvestorPlace.com, Ian Cooper has been analyzing stocks and options for web-based advisories since 1999. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets The post 5 Groovy Psychedelic Stocks to Buy appeared first on InvestorPlace.
The global coronavirus pandemic has created a huge spike in mental health conditions that psychedelic drugs can treat.